Every 10-Q that Apyx Medical Corporation (APYX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APYX filings page.
Apyx Medical Corporation reported Q2 2026 sales of $13,884 (in thousands), up 22.1% year over year, and six‑month sales of $26,374 (in thousands), up 26.8%. Growth was driven by the Surgical Aesthetics segment, which rose 28.1% in Q2 and 31.7% year to date, helped by AYON Body Contouring, higher handpiece volumes and stronger international generator sales.
Gross margin improved to 63.9% in Q2 and 63.7% for the first half. The company still posted losses: Q2 net loss attributable to stockholders was $3,243 (in thousands), with a six‑month net loss of $5,351 (in thousands), or basic and diluted loss per share of $0.07 and $0.12, respectively. Cash and cash equivalents were $27,617 (in thousands) at June 30, 2026; net cash used in operating activities was $4,062 (in thousands) for the first half.
Apyx carries a $37,500 (in thousands) term loan under its Perceptive Credit Agreement at a 12.0% interest rate and remains in covenant compliance, including Surgical Aesthetics revenue and operating expense targets. The company disclosed ongoing product liability matters with recorded defense cost accruals and a new patent infringement lawsuit filed July 20, 2026, while also highlighting expanded FDA 510(k) clearance for AYON power liposuction and a limited commercial launch started in late June.
Apyx Medical Corporation reported first-quarter 2026 net sales of $12.5 million, up 32.4% from $9.4 million a year earlier, driven mainly by its Surgical Aesthetics segment and the AYON body contouring system. Gross profit rose to $7.9 million, lifting gross margin to 63.5% from 60.1% as higher-margin surgical aesthetics products made up a larger share of revenue.
The company reduced its net loss attributable to stockholders to $2.1 million, or $0.05 per share, compared with a $4.2 million loss, or $0.10 per share, in the prior-year quarter. Operating cash outflow was modest at $0.6 million, and cash and cash equivalents were $31.1 million at March 31, 2026. Apyx carries a $37.5 million term loan under its Perceptive Credit Agreement at a 12.0% interest rate and remains subject to revenue and operating expense covenants.
Management highlights strong growth in Surgical Aesthetics, with segment sales up 36.1% to $10.7 million, and notes that international revenue increased to 35.1% of total sales. At the same time, the company continues to incur recurring net losses and expects near-term losses to continue, indicating an ongoing need to balance growth investments, debt obligations and potential future financing.
Apyx Medical (APYX) reported Q3 2025 results showing higher sales and narrower losses as it launched the AYON Body Contouring System. Revenue was $12.877 million, up 12.1% from $11.487 million a year ago, driven by a 19.1% increase in Surgical Aesthetics to $11.065 million, while OEM declined 17.6% to $1.812 million. Gross margin improved to 64.4% from 60.5%.
Operating loss narrowed to $0.832 million from $3.635 million, and net loss attributable to stockholders improved to $1.984 million (loss per share $0.05) from $4.703 million ($0.14). For the nine months, revenue was $33.680 million versus $33.880 million, with operating cash outflow of $5.471 million improving from $15.110 million.
Liquidity and leverage: Cash and equivalents were $25.135 million versus $31.741 million at year-end. Long‑term debt, net, was $34.607 million on a $37.5 million term loan bearing interest at one‑month SOFR (floor 5.0%) plus 7.0% (12.0% at September 30, 2025). The company was in compliance with covenants. AYON received 510(k) clearance in May and began commercial launch in September; a 510(k) for label expansion was submitted in October. Shares outstanding were 38,241,905 as of November 5, 2025.